The Company has developed an extremely potent siRNA trigger combined with a third generation LNP. Although an ALDH2 inhibition drug already exists (Disulfiram) it has to be taken daily, while TKM-ALDH2 is expected to prolong ethanol sensitivity and overcome the limitations of patient compliance. The Compa